Results 71 to 80 of about 12,412 (210)

Profile of secukinumab in the treatment of psoriasis: current perspectives

, 2015
Michael Roman, Vandana K Madkan, Melvin W Chiu Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA Abstract: Secukinumab (Cosentyx™) is a human monoclonal IgG1k antibody that has been developed to target and ...
Madkan VK, Roman M, Chiu MW
core  

Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease

European Journal of Medical Research
Background Inflammatory bowel disease (IBD) is a rare adverse effect linked to secukinumab, with limited clinical data available. This study aimed to analyze the clinical features of secukinumab-induced IBD and to offer recommendations for the careful ...
Ronghui Li, Haibo Lei, Chunjiang Wang, Xiang Liu   +3 more
doaj   +1 more source

Assessment of Major Adverse Cardiovascular Event Across Diverse Racial Groups of Psoriasis Patients on Biologic Therapy: A Retrospective Cohort Study

The Journal of Dermatology, EarlyView.
ABSTRACT Psoriasis is associated with an increased risk of major adverse cardiovascular events (MACE), and biologic therapy may reduce this risk by targeting systemic inflammation. However, limited data exist on whether long term MACE risk differs by biologic class or across racial groups. We conducted a retrospective cohort study to assess the risk of
Chunghwan Ro, Ana Ormaza Vera, Waleed Adawi, Clinton W. Enos   +3 more
wiley   +1 more source

Secukinumab in the treatment of psoriasis: patient selection and perspectives

, 2018
Eric J Yang,1,2 Kristen M Beck,1 Wilson Liao1 1Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA Abstract ...
Liao W, Yang EJ, Beck KM
core  

Comparative effectiveness of secukinumab and etanercept in biologic-naive patients with psoriatic arthritis assessed by matching-adjusted indirect comparison [PDF]

, 2018
Objective: Matching-adjusted indirect comparison (MAIC) can be used to assess the comparative effectiveness of two treatments indirectly using data from randomized placebo-controlled trials. This MAIC assessed the comparative effectiveness of secukinumab
Matthias Hunger, Choy, Ernest, Gandhi, Kunal, Pricop, Luminita, Jugl, Steffen, Hunger, Matthias, Gandhi, Kunal K, Mease, Philip J, Nash, Peter, Howard Thom, Jugl, Steffen M, Ernest Choy, Luminita Pricop, Thom, Howard, Chrysostomos Kalyvas, Philip Mease, Kunal K. Gandhi, Steffen M. Jugl, Peter Nash, Gandhi, Kunal K., Mease, Philip, Kalyvas, Chrysostomos, Jugl, Steffen M.   +22 more
core   +1 more source

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada, Yoshiko Maeda, Miyuki Hasegawa, Motonobu Sakaguchi, Takamasa Hashimoto, Teruko Narusawa, Nobuyoshi Takabayashi, Tomoko Takahashi, Taisuke Kondo, Shingo Kuroda   +9 more
wiley   +1 more source

Apremilast Coadministered with Secukinumab for Effective Treatment of Acrodermatitis Continua of Hallopeau: A Case Report [PDF]

Xin-Yi Yao,1 Lyu-Ye Liu,1 Jin-Xiang Yuan,1 Chuan-Jian Yuan,1 Jun-Ling Zhang2 1Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, People’ Republic of China; 2Department of Dermatology, Tianjin Academy of Traditional Chinese ...
Yao XY, Zhang JL, Yuan CJ, Liu LY, Yuan JX   +4 more
core  

A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab

Drugs - Real World Outcomes, 2019
Purpose This real-world study evaluated the feasibility of assessing patient-reported symptom improvement and treatment satisfaction using a web-based survey among patients with ankylosing spondylitis (AS) treated with secukinumab.
Marina Magrey, Michael Bozyczko, Daniel Wolin, Margaret Mordin, Lori McLeod, Eric Davenport, Costel Chirila, Yujin Park   +7 more
doaj   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

Inadvertent Overdose of Secukinumab, Consequences, and Cautions

, 2016
Secukinumab, an anti-IL-17A monoclonal antibody, is commonly used for the treatment of psoriasis. The IL-17A cytokine has been linked to immune-mediated disorders, and in the FIXTURE study, secukinumab had proven superior to placebo and etanercept in ...
Dana Alessa, David B. Kessler, Mark Taliercio   +2 more
core   +1 more source